Factors associated with the development of dynapenia in patients with ulcerative colitis

Aim. To evaluate the association of insulin resistance and secretion of neuropeptide Y with dynapenia in patients with ulcerative colitis (UC).
Materials and methods. A single-center observational cross-sectional study included 80 patients with UC. Participants were divided into two groups: patients with dynapenia and patients with normal hand grip strength. The body mass index (BMI), dietary habits and stress levels were studied, patients underwent dynamometry. C-reactive protein (CRP), TNF-α, interleukin-6, leptin, adiponectin, soluble leptin receptors (sOb-R), neuropeptide Y and peptide YY, insulin and glucose were measured in blood serum. We determined the index of insulin resistance HOMA-IR. Median (Me) of the upper and lower quartiles (P₂₅; P₇₅), proportion and standard error of the proportion were calculated. We also determined the Mann-Whitney and Kruskal-Wallis tests, Yates chi-squared test, and twotailed Fischer’s test. The Spearman’s correlation coefficient was calculated.
Results. 54 ± 5.6% of patients with dynapenia were overweight or obese. It should be noted that patients with dynapenia were relatively young (35 (32; 51) years). Dynapenia is associated with increased CRP levels, insulin resistance, and higher values of neuropeptide Y. We found a positive correlation between neuropeptide Y and the consumption of simple carbohydrates and alcoholic beverages. The study did not reveal relationship between the concentration of neuropetide Y and the activity of UC, the localization of the pathological process, and the course of the disease. A positive association between neuropeptide Y and the level of sOb-R, peptide YY, was established.
Conclusion. Long-lasting chronic inflammation leads to the premature development of dynapenia and insulin resistance in patients with UC at a young age. In patients with dynapenia, the level of neuropeptide Y is significantly higher than in patients without dynapenia, which is probably due to the regulation of energy balance, glucose and insulin homeostasis.

1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population‐based studies. Lancet. 2017;390(10114):2769–2778.

2. Бикбавова Г.Р., Ливзан М.А., Шмурыгина Е.А., Михалева Л.В. Избыточный вес и ожирение у больного язвенным колитом: встречаемость и ассоциации. Экспериментальная и клиническая гастроэнтерология. 2020;(10):33–38. DOI: 10.31146/1682-8658-ecg-182-10-33-38.

3. Bischoff S.C., Barazzoni R., Busetto L., Campmans-Kuijpers M., Cardinale V., Chermesh I. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol. J. 2022;10(7):663–720. DOI: 10.1002/ueg2.12280.

4. Бикбавова Г.Р., Ливзан М.А., Лисютенко Н.С., Мартыненко О.В., Индутный А.В. Распространенность избыточной массы тела и ожирения у больных язвенным колитом: исследование случай–контроль. Экспериментальная и клиническая гастроэнтерология. 2023;(4):6–11. DOI: 10.31146/1682-8658-ecg-212-4-6-11.

5. Michalak A., Kasztelan-Szczerbińska B., Cichoż-Lach H. Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review. Nutrients. 2022;14(19):3983. DOI: 10.3390/nu14193983.

6. Bryant R.V., Schultz C.G., Ooi S., Goess C., Costello S.P., Vincent A.D. et al. Obesity in inflammatory bowel disease: gains in adiposity despite high prevalence of myopenia and osteopenia. Nutrients. 2018;10(9):1192. DOI: 10.3390/nu10091192.

7. Маев И.В., Шелыгин Ю.А., Скалинская М.И., Веселов А.В., Сказываева Е.В., Расмагина И.А. и др. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020;75(1):27–35. DOI: 10.15690/vramn1219.

8. Kaplan G.G., Windsor J.W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021;18(1):56–66. DOI: 10.1038/s41575-020-00360-x.

9. He J., Zhang S., Qiu Y., Liu F., Liu Z., Tan J. et al. Ulcerative colitis increases risk of hypertension in a UK biobank cohort study. United European Gastroenterol. J. 2023;11(1):19–30. DOI: 10.1002%2Fueg2.12351.

10. Dhaliwal A., Quinlan J.I., Overthrow K., Greig C., Lord J.M., Armstrong M.J. et al. Sarcopenia in inflammatory bowel disease: a narrative overview. Nutrients. 2021;13(2):656. DOI: 10.3390/nu13020656.

11. Ge X., Xia J., Wu Y., Ye L., Liu W., Qi W. et al. Sarcopenia assessed by computed tomography is associated with colectomy in patients with acute severe ulcerative colitis. Eur. J. Clin. Nutr. 2022;76(3):410–418. DOI: 10.1038/s41430-021-00953-y.

12. Ryan E., McNicholas D., Creavin B., Kelly M.E., Walsh T., Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 2019;25(1):67–73. DOI: 10.1093/ibd/izy212.

13. Peake J.M., Della Gatta P., Suzuki K., Nieman D.C. Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. Exerc. Immunol. Rev. 2015;21:8–25.

14. Бикбавова Г.Р., Ливзан М.А., Тихонравова Д.В. Все, что нужно знать о саркопении: краткий гид для современного терапевта в вопросах и ответах. Бюллетень сибирской медицины. 2023;22(3):88–97. DOI: 10.20538/1682-0363-2023-3-88-97.

15. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169.

16. Бикбавова Г.Р., Ливзан М.А., Драпкина О.М., Лисютенко Н.С., Романюк А.Е. Саркопения и динапения у больных язвенным колитом (кросс-секционное обсервационное исследование). Вестник Российской академии медицинских наук. 2024;79(2):112–122. DOI: 10.15690/vramn17389.

17. Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., Абдулганиева Д.И., Алексеева О.А., Ачкасов С.И. и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7–36. DOI: 10.33878/2073-7556-2019-18-4-7-36.

18. CINDI dietary guide. Document EUR/00/5018028, E70041R. Copenhagen: WHO Regional Office for Europe, 2003:42.

19. Chapman J.M., Reeder L.G., Massey F.J. Jr., E. Borun R., Picken B., Browning G.G. et al. Relationships of stress, tranquilizers, and serum cholesterol levels in a sample population under study for coronary heart disease. Am. J. Epidemiol. 1966;83(3):537–547. DOI: 10.1093/oxfordjournals.aje.a120605.

20. Кардиоваскулярный риск у больных язвенным колитом: технология поддержки врачебных решений: карточка проекта фундаментальных и поисковых научных исследований, поддержанного Российским научным фондом. № 23-25-10035. URL: https://rscf.ru/project/23-25-10035/

21. Ткачук В.А., Воротников А.В. Молекулярные механизмы развития резистентности к инсулину. Сахарный диабет. 2014;17(2):29–40. DOI: 10.14341/DM2014229-40.

22. Lee N.J., Oraha J., Qi Y., Enriquez R.F., Tasan R., Herzog H. Altered function of arcuate leptin receptor expressing neuropeptide Y neurons depending on energy balance. Mol. Metab. 2023;76:101790. DOI: 10.1016/j.molmet.2023.101790.

23. Листопадова А.П., Петренко Ю.В. Нейропептид Y: физиологическая роль и клиническое значение. Медицина: теория и практика. 2018;3(Прил.):157–162.

24. Straub R.H., Herfarth H., Falk W., Andus T., Schölmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J. Neuroimmunol. 2002;126(1-2):116–125. DOI: 10.1016/S0165-5728(02)00047-4.

25. El-Salhy M., Mazzawi T., Gundersen D., Hatlebakk J.G., Hausken T. The role of peptide YY in gastrointestinal diseases and disorders. Int. J. Mol. Med. 2013;31(2):275–282. DOI: 10.3892/ijmm.2012.1222.

26. El-Salhy M., Hausken T. The role of the neuropeptide Y (NPY) family in the pathophysiology of inflammatory bowel disease (IBD). Neuropeptides. 2016;55:137–144. DOI: 10.1016/j.npep.2015.09.005.

27. Lee Y., Im E. Immunomodulatory role of neuropeptide Y in intestinal inflammation. Yakhak Hoeji. 2023;67(1):1–7. DOI: 10.17480/psk.2023.67.1.1.

28. Botelho M., Cavadas C. Neuropeptide Y: an anti-aging player? Trends Neurosci. 2015;38(11):701–711. DOI: 10.1016/j.tins.2015.08.012.